BR112022017923A2 - Tratamento de infecção por coronavírus - Google Patents
Tratamento de infecção por coronavírusInfo
- Publication number
- BR112022017923A2 BR112022017923A2 BR112022017923A BR112022017923A BR112022017923A2 BR 112022017923 A2 BR112022017923 A2 BR 112022017923A2 BR 112022017923 A BR112022017923 A BR 112022017923A BR 112022017923 A BR112022017923 A BR 112022017923A BR 112022017923 A2 BR112022017923 A2 BR 112022017923A2
- Authority
- BR
- Brazil
- Prior art keywords
- coronaviruses
- treat
- virus infection
- corona virus
- treatment
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 4
- 241000711573 Coronaviridae Species 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
TRATAMENTO DE INFECÇÃO POR CORONAVÍRUS. A presente invenção refere-se, de modo geral, aos campos de virologia, doenças infecciosas e medicina e descreve compostos, composições, métodos e kits para o tratamento de doença mediada por CoV, por exemplo, uma doença causada por SARS-CoV-2, SAR8 ou MERS. Mais especificamente, a invenção refere-se a inibidores eficazes de coronavírus, que podem tratar coronavírus, inclusive o novo coronavírus 2019. Em uma modalidade, a invenção fornece um novo uso de WX-671 como um inibidor eficaz de coronavírus e sua aplicação na preparação de medicamentos para tratar infecção por coronavírus em seres humanos. Em uma modalidade, a invenção fornece um novo uso de ABC294640 como um inibidor eficaz de coronavírus e sua aplicação na preparação de medicamentos para tratar infecção por coronavírus em seres humanos.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017923A2 true BR112022017923A2 (pt) | 2022-10-18 |
Family
ID=76548186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017923A BR112022017923A2 (pt) | 2020-03-10 | 2021-03-08 | Tratamento de infecção por coronavírus |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11045453B1 (pt) |
| EP (1) | EP4117630A1 (pt) |
| JP (1) | JP2023517920A (pt) |
| KR (1) | KR20220151613A (pt) |
| CN (2) | CN115515560B (pt) |
| AU (1) | AU2021235304A1 (pt) |
| BR (1) | BR112022017923A2 (pt) |
| CA (1) | CA3174438A1 (pt) |
| IL (1) | IL295658A (pt) |
| MX (1) | MX2022011173A (pt) |
| WO (1) | WO2021181157A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| MX2022011173A (es) * | 2020-03-10 | 2022-10-18 | Redhill Biopharma Ltd | Tratamiento de infeccion por coronavirus. |
| US11471448B2 (en) * | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (zh) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 |
| EP4286851A1 (en) * | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| DE59909210D1 (de) | 1998-07-20 | 2004-05-19 | Wilex Ag | Urokinase-Inhibitoren |
| ES2188003T3 (es) | 1998-09-18 | 2003-06-16 | Pentapharm Ag | Inhibidores de la uroquinasa. |
| WO2002074756A2 (de) | 2001-03-21 | 2002-09-26 | Pentapharm Ag | Urokinase-inhibitoren |
| CH695999A5 (de) | 2002-02-28 | 2006-11-15 | Wilex Ag | Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten. |
| AU2003253326A1 (en) | 2002-07-25 | 2004-02-16 | Wilex Ag | Method for the production of phenylalanine derivatives |
| DE10238048A1 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur Herstellung von Phenylalanin-Derivaten |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (de) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stabile Dosierungsform von Phenylalanin-Derivaten |
| CA2583771C (en) | 2004-10-14 | 2013-08-27 | Wilex Ag | Method for cleaning 3-hydroxyamidinophenylalanine derivatives by the precipitation and recrystallization of salt and an aromatic sulfonic acid |
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| CN101248041B (zh) | 2005-06-17 | 2013-11-20 | 艾宝奇生物工艺有限公司 | 鞘氨醇激酶抑制剂 |
| US9687477B2 (en) | 2011-06-01 | 2017-06-27 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand RNA virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
| PL3297438T3 (pl) * | 2015-05-21 | 2022-02-21 | Chemocentryx, Inc. | Modulatory ccr2 |
| AU2016336133B2 (en) * | 2015-10-06 | 2021-02-25 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| MX2022011173A (es) * | 2020-03-10 | 2022-10-18 | Redhill Biopharma Ltd | Tratamiento de infeccion por coronavirus. |
-
2021
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/es unknown
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-03-08 JP JP2022554382A patent/JP2023517920A/ja active Pending
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/zh active Active
- 2021-03-08 CN CN202311591091.6A patent/CN117695284A/zh active Pending
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/ko unknown
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en unknown
- 2021-03-08 EP EP21768527.0A patent/EP4117630A1/en active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/pt unknown
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US20210322390A1/en active Pending
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11918560B2 (en) | 2024-03-05 |
| US11052073B1 (en) | 2021-07-06 |
| US20210322390A1 (en) | 2021-10-21 |
| MX2022011173A (es) | 2022-10-18 |
| AU2021235304A1 (en) | 2022-10-06 |
| CN115515560B (zh) | 2023-12-15 |
| CN117695284A (zh) | 2024-03-15 |
| JP2023517920A (ja) | 2023-04-27 |
| CA3174438A1 (en) | 2021-09-16 |
| WO2021181157A1 (en) | 2021-09-16 |
| US20210299108A1 (en) | 2021-09-30 |
| KR20220151613A (ko) | 2022-11-15 |
| US20220031682A1 (en) | 2022-02-03 |
| IL295658A (en) | 2022-10-01 |
| US11364227B2 (en) | 2022-06-21 |
| CN115515560A (zh) | 2022-12-23 |
| EP4117630A1 (en) | 2023-01-18 |
| US11045453B1 (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017923A2 (pt) | Tratamento de infecção por coronavírus | |
| Rajasekaran et al. | Identification of traditional medicinal plant extracts with novel anti-influenza activity | |
| AU2021260618A8 (en) | Antiviral application of nucleoside analog or combination formulation containing nucleoside analog | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| BRPI0210076A8 (pt) | Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BRPI0517934A (pt) | métodos de captura, inativação e remoção de infecções virais mediante a administração de composições para o trato respiratório | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| BRPI0411900B8 (pt) | compostos e composições farmacêuticas compreendendo os mesmos | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| BR112022017209A2 (pt) | Uso de composto nucleosídeo no tratamento de doenças infecciosas por coronavírus | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BRPI0516542A (pt) | composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária | |
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BR112022010798A2 (pt) | Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo | |
| BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
| BR112022015046A2 (pt) | Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo | |
| BRPI0418103A (pt) | extrato aquoso do córtex da canela, uso de um extrato de canela, composição, métodos para o tratamento de um paciente que esteja sofrendo de infecção viral e para desinfetar uma área suspeita de ter sido contaminada com vìrus, filtro, método para produzir um vìrus neutralizado para imunização, vìrus neutralizado, formulação de vacina e, método de imunização contra infecção viral | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| BR0112580A (pt) | Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral | |
| BRPI0606997A2 (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos |